Graft Versus Host Disease (GVHD)

Ruxolitinib Improves Outcomes in aGVHD Across Subgroups

Original Publication Date
Article Source
External Web Content
Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease (aGVHD), according to data from the REACH2 trial presented at the 25th Annual European Hematology Congress. (continued at link)

Guidance for Bone Marrow Failure Patients to Protect Against Coronavirus (COVID-19)

This content has been prepared in consultation with AAMDSIF Medical Advisory Board Chair Mikkael Sekeres MD, MS of Sylvester Comprehensive Cancer Center, University of Miami and Co-Chair Olatoyosi Odenike MD of the University of Chicago with additional review by Amy DeZern, MD, Johns Hopkins and Carlos De Castro, MD, Duke. ( November 2022)

Subscribe to Graft Versus Host Disease (GVHD)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.